Overview

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.
Phase:
Phase 3
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
Vedolizumab